To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The aim of the study is:
To evaluate the tolerance of lanthanum polystyrene sulfonate powder in patients with
end-stage renal disease (ESRD-HD) hyperphosphatemia with multiple doses and multiple doses；
To evaluate the pharmacodynamics of lanthanum polystyrene sulfonate powder in
hyperphosphatemia patients with end-stage renal disease on hemodialysis (ESRD-HD); To
evaluate the pharmacokinetics of lanthanum polystyrene sulfonate powder in patients with
end-stage renal disease (ESRD-HD) hyperphosphatemia after multi-dose and multiple
administration.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Grand Life Science (Liaoning) Co., Ltd. Liaoning Grand Nuokang Biopharmaceutical Co., Ltd.
Collaborators:
First Hospital of Jilin University The First Hospital of Jilin University